ArticleFrontiers in veterinary science2026
A zingiberene-selenium nanoparticle formulation modulates oxidative, inflammatory, and osteogenic responses during femoral fracture healing in rats.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bone fracture healing involves coordinated inflammatory, oxidative, and remodeling processes. This study evaluated free zingiberene and a zingiberene-selenium nanoparticle (zingiberene-SeNP) formulation in a rat femoral fracture model. Methods: Twenty-four adult male Wistar rats were assigned to intact control, fracture control, fracture plus zingiberene (10 mg/kg/day), or fracture plus zingiberene-SeNP formulation (0.5 mg/kg/day, expressed as total administered formulation mass) groups for 35 days. Outcomes included serum calcium, phosphate, magnesium, and alkaline phosphatase (ALP); malondialdehyde (MDA), nitric oxide (NO), reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT); C-reactive protein (CRP), cyclooxygenase-2 (COX-2), prostaglandin E₂ (PGE₂), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and nuclear factor-kappa B (NF-κB); C-terminal telopeptide of type I collagen (CTX-I), calcitonin, osteocalcin, osteoprotegerin (OPG), and bone morphogenetic protein-1 (BMP-1), together with radiographic and hematoxylin and eosin (H&E) histology. Results: Fracture disrupted mineral, oxidative, inflammatory, and bone-turnover profiles. Both treatments improved multiple biochemical and inflammatory indices versus fracture control. The zingiberene-SeNP formulation showed stronger effects than free zingiberene for selected endpoints, including MDA, GSH, ALP, PGE₂, TNF-α, IL-1β, NF-κB, CTX-I, calcitonin, osteocalcin, OPG, and BMP-1. Radiographic and histological findings were consistent with improved callus organization and bone maturation. Discussion: Overall, both treatments favorably modulated fracture-repair responses, with greater effects of the nanoformulation for selected parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.